Ironwood Pharmaceuticals Company Insiders

IRWD Stock  USD 7.82  0.26  3.22%   
Ironwood Pharmaceuticals employs about 267 people. The company is managed by 37 executives with a total tenure of roughly 235 years, averaging almost 6.0 years of service per executive, having 7.22 employees per reported executive. Evaluation of Ironwood Pharmaceuticals' management performance can provide insight into the firm performance.
Mark Mallon  CEO
CEO, Director
Peter Hecht  CEO
Co-Founder, CEO and Director

Ironwood Pharmaceuticals' Insider Buying Vs Selling

50

 
Selling
 
Buying

Latest Trades

2024-03-06Jon R DuaneAcquired 6920 @ 8.7View
2024-03-04Sravan Kumar EmanyAcquired 10684 @ 9.38View
2024-02-12Thomas A MccourtDisposed 177164 @ 15.24View
2023-09-15Sravan Kumar EmanyAcquired 36072 @ 8.32View
2023-05-30Thomas A MccourtDisposed 26632 @ 10.7View
2023-05-08Thomas A MccourtDisposed 21148 @ 10.62View
Monitoring Ironwood Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

Ironwood Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Ironwood Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Ironwood will maintain a workforce of about 270 employees by May 2024.
 
Credit Downgrade
 
Yuan Drop
 
Covid

Ironwood Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.1339 % which means that it generated a profit of $0.1339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.7404) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.
The current year's Net Income Applicable To Common Shares is expected to grow to about 211.4 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 137.1 M.

Ironwood Pharmaceuticals Workforce Comparison

Ironwood Pharmaceuticals is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 2.91 Million. Ironwood Pharmaceuticals adds roughly 267 in number of employees claiming only tiny portion of equities under Health Care industry.

Ironwood Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (2.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.740.9964
Way Down
Very volatile

Ironwood Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ironwood Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
2.8333
17
6
 1,273,918 
 322,248 
2023-12-01
0.6667
2
3
 2,919 
 19,874 
2023-09-01
2.0
4
2
 47,968 
 9,021 
2023-06-01
2.0
10
5
 181,745 
 100,409 
2023-03-01
0.8261
19
23
 1,064,751 
 543,747 
2022-12-01
0.2
1
5
 1,244 
 56,494 
2022-09-01
0.1818
2
11
 19,415 
 213,572 
2022-06-01
0.8571
12
14
 386,966 
 659,266 
2022-03-01
0.6316
12
19
 665,261 
 120,262 
2021-12-01
0.4444
4
9
 89,183 
 168,402 
2021-09-01
1.25
5
4
 103,820 
 10,910 
2021-06-01
3.75
15
4
 339,097 
 27,880 
2021-03-01
1.1579
22
19
 2,991,090 
 88,845 
2020-12-01
0.6
9
15
 183,946 
 227,633 
2020-09-01
0.3333
1
3
 1,600 
 9,214 
2020-06-01
0.4074
11
27
 219,059 
 375,059 
2020-03-01
0.3462
9
26
 576,527 
 341,666 
2019-12-01
0.8333
5
6
 207,020 
 4,834 
2019-09-01
0.3571
5
14
 249,192 
 499,497 
2019-06-01
1.375
44
32
 1,102,981 
 3,486,670 
2019-03-01
0.4595
17
37
 3,047,252 
 3,020,904 
2018-12-01
0.7727
17
22
 6,090,398 
 6,368,689 
2018-09-01
0.8947
17
19
 306,489 
 536,123 
2018-06-01
5.0
10
2
 130,045 
 3,500 
2018-03-01
1.0769
14
13
 1,619,537 
 139,812 
2017-12-01
0.4
4
10
 140,159 
 259,269 
2017-09-01
0.3333
1
3
 153.00 
 3,707 
2017-06-01
2.2
11
5
 190,142 
 133,200 
2017-03-01
0.9
18
20
 1,752,199 
 434,978 
2016-12-01
1.0
5
5
 324,822 
 333,700 
2016-09-01
1.0
2
2
 332.00 
 3,407 
2016-06-01
2.6
13
5
 208,234 
 32,475 
2016-03-01
1.0
17
17
 1,990,478 
 955,505 
2015-12-01
1.0
6
6
 348,569 
 423,733 
2015-09-01
4.0
4
1
 7,934 
 3,725 
2015-03-01
0.8519
23
27
 1,451,490 
 2,853,856 
2014-12-01
0.6429
9
14
 156,803 
 322,164 
2014-09-01
4.5
9
2
 2,225,705 
 65,407 
2014-06-01
1.3846
18
13
 259,192 
 896,914 
2014-03-01
0.7333
22
30
 926,411 
 3,327,497 
2013-12-01
1.8571
13
7
 3,701,748 
 601,080 
2013-09-01
5.5
11
2
 104,727 
 950,000 
2013-06-01
2.8
14
5
 263,976 
 382,434 
2013-03-01
1.3889
25
18
 1,256,501 
 5,061,731 
2012-12-01
1.1053
21
19
 180,196 
 450,566 
2012-09-01
0.2903
9
31
 3,978 
 942,455 
2012-06-01
2.0
8
4
 165,911 
 156,874 
2012-03-01
2.0
10
5
 596,956 
 1,343,656 
2011-12-01
3.0
12
4
 84,233 
 197,174 
2011-09-01
5.0
10
2
 69,797 
 66,666 
2011-06-01
1.1111
10
9
 61,674 
 644,400 
2011-03-01
0.9286
13
14
 181,953 
 165,621 
2010-03-01
0.1579
3
19
 20,366 
 10,617,262 

Ironwood Pharmaceuticals Notable Stakeholders

An Ironwood Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ironwood Pharmaceuticals often face trade-offs trying to please all of them. Ironwood Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ironwood Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark MallonCEO, DirectorProfile
Peter HechtCo-Founder, CEO and DirectorProfile
Bryan RobertsIndependent Chairman of the BoardProfile
Christopher WrightSenior Vice President - Global Development and Chief Development OfficerProfile
Halley GilbertSenior Vice President Chief Legal Officer, SecretaryProfile
Kelly MacDonaldChief Accounting Officer, Vice President - FinanceProfile
Mark CurrieChief Scientific Officer, Sr. VP and President of RandDProfile
Gina ConsylmanInterim CFOProfile
Thomas GraneyCFO and Sr. VP of Fin. and Corporate StrategyProfile
William HuyettCOOProfile
Thomas McCourtChief Commercial Officer and Sr. VP of Marketing and SalesProfile
Julie McHughIndependent DirectorProfile
Christopher WalshIndependent DirectorProfile
Lawrence OlanoffDirectorProfile
Matt RoacheDirector RelationsProfile
Andrew DreyfusDirectorProfile
Douglas WilliamsDirectorProfile
Edward OwensIndependent DirectorProfile
Amy SchulmanDirectorProfile
George ConradesIndependent DirectorProfile
Terrance McGuireIndependent DirectorProfile
Meredith KayaDirector - Investor RelationsProfile
Marla KesslerDirectorProfile
Marsha FanucciIndependent DirectorProfile
Catherine MoukheibirDirectorProfile
Jon DuaneDirectorProfile
MPH MDVP DevelopmentProfile
Jana NoeldekeBasel LeaderProfile
Ronald SilverCorporate OfficerProfile
Sravan EmanyPrincipal VPProfile
Jason RickardVP COOProfile
Mike NanfitoVice ExcellenceProfile
Michael MDSenior OfficerProfile
Marcel MoulaisonVice OperationsProfile
Beth CalitriHead RelationsProfile
John MinardoChief VPProfile
Greg MartiniVice RelationsProfile

About Ironwood Pharmaceuticals Management Performance

The success or failure of an entity such as Ironwood Pharmaceuticals often depends on how effective the management is. Ironwood Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ironwood management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ironwood management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(2.14)(2.04)
Return On Capital Employed 1.07  1.13 
Return On Assets(2.13)(2.02)
Return On Equity 2.89  3.04 
The data published in Ironwood Pharmaceuticals' official financial statements usually reflect Ironwood Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Ironwood Pharmaceuticals. For example, before you start analyzing numbers published by Ironwood accountants, it's critical to develop an understanding of what Ironwood Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Ironwood Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ironwood Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Ironwood Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ironwood Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Ironwood Pharmaceuticals' management manipulating its earnings.

Ironwood Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Ironwood Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ironwood Pharmaceuticals within its industry.

Ironwood Pharmaceuticals Manpower Efficiency

Return on Ironwood Pharmaceuticals Manpower

Revenue Per Employee1.7M
Revenue Per Executive12M
Net Loss Per Employee3.8M
Net Loss Per Executive27.1M
When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Ironwood Stock analysis

When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.69)
Earnings Share
(6.45)
Revenue Per Share
2.848
Quarterly Revenue Growth
0.097
Return On Assets
0.1339
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.